Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From argenx N.V.

Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success

Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren told In Vivo sister publication Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.

Launches Business Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Axsome gets broad label for new depression drug; Argenx CEO on Vyvgart’s success; Chinese firms delist from US; solid results for Novo Nordisk’s new diabetes combo; and women leaders herald change at foreign firms in India.

Commercial Companies

Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success

Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren tells Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.  

Launches Business Strategies

Genentech’s Subcutaneous Tecentriq Shows Non-Inferiority To I.V. Formulation

The Roche affiliate hopes to bring subcutaneous Tecentriq to market, offering patient and clinician advantages while also beating Merck’s Keytruda and Bristol’s Opdivo to the finish line

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • arGEN-X N.V.
UsernamePublicRestriction

Register